Disclosures for "Assessing the Relationship Between Immunoglobulin G Level and Efficacy of Nipocalimab Measured Using Myasthenia Gravis-activities of Daily Living scale"
-
Dr. Mahuwala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Mahuwala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for academic CME. Dr. Mahuwala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen Scientific affairs. Dr. Mahuwala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for amgen. The institution of Dr. Mahuwala has received research support from UCB, . The institution of Dr. Mahuwala has received research support from Alexion . The institution of Dr. Mahuwala has received research support from argenx . The institution of Dr. Mahuwala has received research support from immunovant.
-
Mr. Faelens has received personal compensation for serving as an employee of J&J Innovative Medicine.
-
Dr. Valenzuela has nothing to disclose.
-
Mrs. Neyens has received personal compensation for serving as an employee of Johnson&Johnson.
-
Dr. Zhu has received personal compensation for serving as an employee of Johnson & Johnson.
-
Dr. Leu has received personal compensation for serving as an employee of Johnson and Johnson. Dr. Leu has stock in Johnson and Johnson.
-
Dr. Fitzgibbon has stock in Johnson & Johnson.
-
Author has nothing to disclose
-
Author has nothing to disclose